Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
The Lilly Biotechnology Center in San Diego, California, on March 1, 2023.
Mike Blake | Reuters
Eli Lilly On Thursday, he reported mixed results for the fourth quarter, since the sales of its great Zepbound weight loss and Drug Mounjaro Drugs shot themselves, but saw lower prices.
The figures were consistent with the preliminary results that Eli Lilly shared in January, which disappointed investors. Eli Lilly had He cut his 2024 income guideAs he said that the demand for his weight loss and his diabetes drugs would not meet their high expectations.
The company’s quarterly profits exceeded Wall Street estimates, but sales fell short.
The pharmaceutical giant also issued a fiscal tax earning guide from $ 22.05 to $ 23.55 per share, which is in line with what analysts expected. Eli Lilly reiterated his 2025 fiscal sales guide from $ 58 billion to $ 61 billion.
This is what Eli Lilly reported for the fourth quarter compared to what Wall Street expected, based on a LSEG analysts survey:
- Profit per action: $ 5.32 adjusted compared to $ 4.95 expected
- Revenue: $ 13.53 billion compared to $ 13.57 billion expected
The company registered income from the fourth quarter of $ 13.53 billion, an increase of 45% since the same period of the previous year.
The pharmaceutical giant reserved a net income of $ 4.41 billion, or $ 4.88 per share, for the fourth quarter. That is compared with a gain of $ 2.19 billion, or $ 2.42 per share, a year earlier.
Excluding unique articles associated with the value of intangible assets and other adjustments, Eli Lilly recorded $ 5.32 for action for the fourth quarter of 2024.
This story is developing. Consult the updates again.
